The field of tumor treatment has reached a significant milestone with the introduction of immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [1]. This evidence concerns the gene CD274 and neoplasm.